Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's State FDA Steps Up Transparency With First Annual Review Of Drug Approval Process, Outcome

This article was originally published in PharmAsia News

Executive Summary

BEIJING - In a step toward lifting a longstanding veil on the drug review process in China, the State FDA has for the first time issued a public outline of the range and types of medicines approved by regulators last year

You may also be interested in...



China’s SFDA Aims To Increase Drug Approval Efficiency

In the coming years, SFDA will continue to drive drug approval efficiency to shorten drug review timelines.

3SBio Discontinues NuLeusin; Sinovac To Benefit From Government Vaccine Supply Plan: China Earnings Roundup (Part 3)

China's generic pharma companies suffered a slowdown in Q3, but biotech companies saw healthy growth.

China Drug Approvals Up 26%, Mostly Due To Generics

China's State FDA increased drug approvals by more than 26% in 2010, with the boost largely due to an increase in generic drug approvals. The agency also cleared more clinical trials for drugs that treat diseases that have a large societal impact, according to SFDA's second annual report on the status of drug approvals

Related Content

UsernamePublicRestriction

Register

SC076039

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel